Pfizer Inc. Stock
With 28 Buy predictions and 2 Sell predictions Pfizer Inc. is one of the favorites of our community.
With a target price of €36.00 there is a positive potential of 29.894% for Pfizer Inc. compared to the current price of €27.72.
Our community identified positive and negative aspects for Pfizer Inc. stock for the coming years. 7 users see the criterium "Brand" as a plus for the Pfizer Inc. stock. On the other hand our users think that "Non-cyclic/Cyclic" could be a problem in the future.
Pros and Cons of Pfizer Inc. in the next few years
Performance of Pfizer Inc. vs. its peers
|Eli Lilly Corp.||-0.460%||-1.948%||-0.732%||32.077%||23.665%||163.244%||151.248%|
|Alexion Pharmaceutical Inc.||-0.550%||-2.577%||-3.215%||39.169%||-0.657%||35.676%||-1.854%|
|Johnson & Johnson||1.060%||-2.835%||-0.595%||-0.669%||5.945%||24.590%||40.178%|
Other discussions about Pfizer Inc. StockNew thread Forum
U.S. FDA Accepts for Priority Review Pfizer’s Application for TicoVac™ (Tick-borne Encephalitis Vaccine)
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review the company’s Biologics License Application (BLA) for TicoVac™, its tick-borne
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Angela Hwang, Group President, Pfizer Biopharmaceuticals Group, at the Cowen 41st Annual
Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma
Pfizer Inc. (NYSE:PFE) today announced that the first participant has been dosed in the registration-enabling Phase 2 MagnetisMM-3 study (NCT04649359) of elranatamab (PF-06863135), an